CHMP issues positive opinion for Libtayo® (cemiplimab) in advanced cutaneous squamous cell carcinoma

NEXT STORY
Sanofi: FDA approves Praluent® (alirocumab) to prevent heart attack, stroke and unstable angina requiring hospitalization
PREV STORY
Akari Therapeutics Announces Expanded Ophthalmology Program Based on Positive Emerging Data on LTB4-C5 Dual Action in Surface and Back of the Eye Diseases
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction in circulating tumor DNA (ctDNA) while on tebentafusp is associated with overall survival in the Phase 2 clinical trial

author_avatar
NASDAQ Market News

Tetra Bio-Pharma Signs Definitive Commercialization Agreement for CAUMZ™ in Mexico With Alternavida S.A.

author_avatar
NASDAQ Market News

AnaptysBio Announces Positive Top-Line Proof-of-Concept Data For ANB020 In Moderate-to-Severe Baseline Adult Peanut Allergy Patients

46% of adult peanut allergy patients with moderate-to-severe baseline symptoms tolerated 500mg cumulative peanut ...

author_avatar
NASDAQ Market News